Bayer HealthCare Enters into Distribution Agreement to Expand Markets for the
Medrad™ Intego™ PET Infusion System
LEVERKUSEN, Germany and TARRYTOWN, N.Y., March 5, 2013
LEVERKUSEN, Germany and TARRYTOWN, N.Y., March 5, 2013 /PRNewswire/ --Bayer
HealthCare is expanding its global distribution network for the Medrad™
Intego™ PET Infusion System through a new distribution agreement with Comecer,
SPA, a world leader in protection technologies in nuclear medicine. Through
this agreement, Bayer and Comecer are providing customers with an integrated
nuclear medicine solution – combining the clinical administration capabilities
of Intego with the Comecer's protection technologies for PET/CT^ centers
around the world.
According to Doug Descalzi, Bayer HealthCare's Sr. Director of Molecular
Imaging Devices, this distribution agreement capitalizes on the strength of
both companies. "This arrangement creates an end-to-end solution for
customers, from isotope production to radiopharmaceutical infusion. We're
pleased to be working with Comecer to not only provide greater patient access
to Intego but also to provide comprehensive product solutions to nuclear
medicine suites around the world."
Intego is a worldwide market leader in PET/CT, and the only FDA-cleared system
for administration of 18F-FDG and 18F-NaF. Intego infuses doses on-demand,
providing clinicians with greater flexibility, enhanced workflow, added
protection and more accurate, repeatable, patient-specific dosing. Now,
through distribution with Comecer, clinicians in Europe and other markets will
have easier access to this radiation dose reducing technology.
"Bayer has demonstrated incredible benefits to nuclear medicine facilities
with the Intego PET Infusion System," said Emiliano Spagnolo, Director of
Sales and Business Development for Comecer. "We are thrilled to take part in
extending Intego to customers as part of our portfolio of solutions."
Since its launch in 2008, Bayer HealthCare has continued to enhance the Intego
platform, adding software features, expanding compatibility and indications,
and significantly reducing the size of the device. Bayer HealthCare will be
showcasing the Intego PET Infusion System at the European Congress of
Radiology (ECR) in Vienna, Austria, March 7-11, 2013.
About Comecer Group
Comecer Group is a world leader in protection technologies, hot cells
manufacturing for nuclear medicine, isolation technology, and nuclear power
plant protection/decommissioning. Comecer Group also produces screening
software systems and equipment for special applications, designed for large
industrial groups and research organizations. It works for hospitals,
universities and pharmaceutical companies on tailored projects for the
production of isolators for the treatment of toxic and hazardous substances.
For more information visit http://www.comecer.com.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of
health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup
of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the
world's leading, innovative companies in the healthcare and medical products
industry and is based in Leverkusen, Germany. The company combines the global
activities of the Animal Health, Consumer Care, Medical Care and
Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop,
manufacture and market products that will improve human and animal health
worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec
31, 2012) and is represented in more than 100 countries. More information at
Our online press service is just a click away: www.press.bayerhealthcare.com
This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. These
factors include those discussed in Bayer's public reports which are available
on the Bayer website at www.bayer.com. The company assumes no liability
whatsoever to update these forward-looking statements or to conform them to
future events or developments.
^ PET = positron emission tomography; CT = computer tomography
SOURCE Bayer HealthCare
Contact: For the US: Alicia Cafardi, Phone: +1-724-940-8621,
email@example.com; For ex-US: Dr Gisela Lenz, Phone: +49 214 30-58030,
firstname.lastname@example.org, lz (2013-0140E)
Press spacebar to pause and continue. Press esc to stop.